Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: A comparison to human α1- and α2-adrenoceptor subtypes

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 1-9

  Amphoux, Anne ^a,b,c   Millan, Mark J ^d   Cordi, Alex ^d   Bönisch, Heinz ^e   Vialou, Vincent ^a,b,c,f   Mannoury la Cour, Clotilde ^d   Dupuis, Delphine S ^d   Giros, Bruno ^a,b,c   Gautron, Sophie ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^e UNIVERSITY OF BONN   (Germany)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Disprocynium24; Organic cation transporter; Uptake; Adrenoceptor

Indexed keywords

1 (BIPHENYL 2 YLOXY) 4 IMINO 4 PIPERIDIN 1 YLBUTAN 2 OL; 1 METHYL 4 PHENYLPYRIDINIUM; 1,1' DIETHYL 2,4 CYANINE IODIDE; 1,1' DIISOPROPYL 2,4 CYANINE IODIDE; 1,1' DIMETHYL 2,4 CYANINE IODIDE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 4 (6,7 DIHYDROBENZO[B]THIOPHEN 4 YL) 1H IMIDAZOLE; 6,7 DIHYDRO 4 (4 IMIDAZOLYL)BENZO[B]THIOPHENE; AAC 291; AAC 301; ADRENERGIC RECEPTOR AFFECTING AGENT; AH 11110A; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PROTEIN INHIBITOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DISPROCYNIUM 24; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 3; QUINOLINE DERIVATIVE; SLC22A7 PROTEIN, HUMAN;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSPORT KINETICS; XENOBIOTIC METABOLISM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; DOSE RESPONSE; HAMSTER; MALE; METABOLISM; RAT; SPECIES DIFFERENCE; WISTAR RAT;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORTER 1; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; SPECIES SPECIFICITY;

EID: 77951247170     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.012     Document Type: Article

References (52)

1. Amphoux A., Vialou V., Drescher E., Bruss M., Mannoury La Cour C., Rochat C., Millan M.J., Giros B., Bonisch H., Gautron S. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 2006, 50:941-952.
2. Asaka J., Terada T., Okuda M., Katsura T., Inui K. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm. Res. 2006, 23:697-704.
3. Assari T., Cox S., Munday M.R., Pearce B. Regulation of alpha(1)-adrenoceptor-linked phosphoinositide metabolism in cultured glia: involvement of protein phosphatases and kinases. Cell. Signal. 2003, 15:403-412.
4. Baganz N.L., Horton R.E., Calderon A.S., Owens W.A., Munn J.L., Watts L.T., Koldzic-Zivanovic N., Jeske N.A., Koek W., Toney G.M., Daws L.C. Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18976-18981.
5. Chen Y., Li S., Brown C., Cheatham S., Castro R.A., Leabman M.K., Urban T.J., Chen L., Yee S.W., Choi J.H., Huang Y., Brett C.M., Burchard E.G., Giacomini K.M. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 2009, 19:497-504.
6. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
7. Ciarimboli G., Schlatter E. Regulation of organic cation transport. Pflugers Arch. 2005, 449:423-441.
8. Ciarimboli G., Koepsell H., Iordanova M., Gorboulev V., Durner B., Lang D., Edemir B., Schroter R., Van Le T., Schlatter E. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J. Am. Soc. Nephrol. 2005, 16:1562-1570.
9. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., Jackson-Lewis V., Javitch J.A., Ballatori N., Przedborski S., Tieu K. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8043-8048.
10. Daws L.C. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol. Ther. 2009, 121:89-99.
11. Eisenhofer G., McCarty R., Pacak K., Russ H., Schomig E. Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 354:287-294.
12. Eltze M., Konig H., Ullrich B., Grebe T. Failure of AH11110A to functionally discriminate between alpha(1)-adrenoceptor subtypes A, B and D or between alpha(1)- and alpha(2)-adrenoceptors. Eur. J. Pharmacol. 2001, 415:265-276.
13. Fritschy J.M., Grzanna R. Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system?. Prog. Brain Res. 1991, 88:257-268.
14. Giardina D., Crucianelli M., Romanelli R., Leonardi A., Poggesi E., Melchiorre C. Synthesis and biological profile of the enantiomers of [4-(4-amino-6, 7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin- 1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B- adrenoceptor antagonist. J. Med. Chem. 1996, 39:4602-4607.
15. Gorbunov D., Gorboulev V., Shatskaya N., Mueller T., Bamberg E., Friedrich T., Koepsell H. High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and blocks transport after mutations in a modeled interaction domain between two helices. Mol. Pharmacol. 2008, 73:50-61.
16. Graefe K.H., Friedgen B., Wolfel R., Bossle F., Russ H., Schomig E. 1, 1'-Diisopropyl-2, 4'-cyanine (disprocynium24), a potent uptake2 blocker, inhibits the renal excretion of catecholamines. Naunyn Schmiedebergs Arch. Pharmacol. 1997, 356:115-125.
17. Grundemann D., Babin-Ebell J., Martel F., Ording N., Schmidt A., Schomig E. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J. Biol. Chem. 1997, 272:10408-10413.
18. Grundemann D., Schechinger B., Rappold G.A., Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1998, 1:349-351.
19. Grundemann D., Koschker A.C., Haag C., Honold C., Zimmermann T., Schomig E. Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells. Br. J. Pharmacol. 2002, 137:910-918.
20. Grzanna R., Berger U., Fritschy J.M., Geffard M. Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. J. Histochem. Cytochem. 1989, 37:1435-1442.
21. Hayer-Zillgen M., Bruss M., Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 2002, 136:829-836.
22. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984, 23:5036-5041.
23. Invernizzi R.W., Garattini S. Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:819-827.
24. Iversen L.L. The uptake of catecholamines at high perfusion concentrations in the rat isolated heart: a novel catechol amine uptake process. Br. J. Pharmacol. 1965, 25:18-33.
25. Jonker J.W., Wagenaar E., Mol C.A., Buitelaar M., Koepsell H., Smit J.W., Schinkel A.H. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell. Biol. 2001, 21:5471-5477.
26. Jonker J.W., Wagenaar E., Van Eijl S., Schinkel A.H. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell. Biol. 2003, 23:7902-7908.
27. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 2007, 24:1227-1251.
28. Lei B., Zhang Y., Han C. Changes in mRNA expression induced by sustained noradrenaline stimulation are different for alpha1-adrenoceptor subtypes in HEK293 cells. Clin. Exp. Pharmacol. Physiol. 2002, 29:1084-1090.
29. Lyles G.A., Callingham B.A. The effect of DSP-4 (N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine) on monoamine oxidase activities in tissues of the rat. J. Pharm. Pharmacol. 1981, 33:632-638.
30. Lyons W.E., Fritschy J.M., Grzanna R. The noradrenergic neurotoxin DSP-4 eliminates the coeruleospinal projection but spares projections of the A5 and A7 groups to the ventral horn of the rat spinal cord. J. Neurosci. 1989, 9:1481-1489.
31. Mamiya N., Goldenring J.R., Tsunoda Y., Modlin I.M., Yasui K., Usuda N., Ishikawa T., Natsume A., Hidaka H. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93. Biochem. Biophys. Res. Commun. 1993, 195:608-615.
32. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 2006, 110:135-370.
33. Millan M.J., Lejeune F., Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 2000, 14:114-138.
34. Millan M.J., Cussac D., Gobert A., Lejeune F., Rivet J.M., Mannoury La Cour C., Newman-Tancredi A., Peglion J.L. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. J. Pharmacol. Exp. Ther. 2004, 309:903-920.
35. Minuesa G., Volk C., Molina-Arcas M., Gorboulev V., Erkizia I., Arndt P., Clotet B., Pastor-Anglada M., Koepsell H., Martinez-Picado J. Transport of lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J. Pharmacol. Exp. Ther. 2009, 329:252-261.
36. Nakayama H., Kitaichi K., Ito Y., Hashimoto K., Takagi K., Yokoi T., Takagi K., Ozaki N., Yamamoto T., Hasegawa T. The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats. Brain Res. 2007, 1184:260-269.
37. Newman-Tancredi A., Nicolas J.P., Audinot V., Gavaudan S., Verriele L., Touzard M., Chaput C., Richard N., Millan M.J. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 358:197-206.
38. Olli-Lahdesmaki T., Tiger M., Vainio M., Scheinin M., Kallio J. Ligand-induced alpha2-adrenoceptor endocytosis: relationship to Gi protein activation. Biochem. Biophys. Res. Commun. 2004, 321:226-233.
39. Ross T.M., Jetter M.C., McDonnell M.E., Boyd R.E., Connelly C.D., Martinez R.P., Lewis M.A., Codd E.E., Raffa R.B., Reitz A.B. alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1, 3-dimethyl-6, 7-dihydrothianaphthene as a high-affinity ligand for the alpha(2D) adrenergic receptor. J. Med. Chem. 2000, 43:765-768.
40. Russ H., Engel W., Schomig E. Isocyanines and pseudoisocyanines as a novel class of potent noradrenaline transport inhibitors: synthesis, detection, and biological activity. J. Med. Chem. 1993, 36:4208-4213.
41. Russ H., Friedgen B., Konigs B., Schumacher C., Graefe K.H., Schomig E. Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 354:268-274.
42. Shu Y., Leabman M.K., Feng B., Mangravite L.M., Huang C.C., Stryke D., Kawamoto M., Johns S.J., DeYoung J., Carlson E., Ferrin T.E., Herskowitz I., Giacomini K.M. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5902-5907.
43. Song I.S., Shin H.J., Shin J.G. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 2008, 38:1252-1262.
44. Trendelenburg U. The extraneuronal uptake and metabolism of catecholamines. Handbook of Experimental Pharmacology 1988, Vol. 90/I:279-319. Springer, Berlin. U. Trendelenburg, N. Weiner (Eds.).
45. Vialou V., Amphoux A., Zwart R., Giros B., Gautron S. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J. Neurosci. 2004, 24:2846-2851.
46. Vialou V., Balasse L., Callebert J., Launay J.M., Giros B., Gautron S. Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J. Neurochem. 2008, 106:1471-1482.
47. Wang Z.J., Yin O.Q., Tomlinson B., Chow M.S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics 2008, 18:637-645.
48. Wilkinson S.E., Parker P.J., Nixon J.S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem. J. 1993, 294(Pt 2):335-337.
49. Zaczek R., Fritschy J.M., Culp S., De Souza E.B., Grzanna R. Differential effects of DSP-4 on noradrenaline axons in cerebral cortex and hypothalamus may reflect heterogeneity of noradrenaline uptake sites. Brain Res. 1990, 522:308-314.
50. Zhang L., Dresser M.J., Gray A.T., Yost S.C., Terashita S., Giacomini K.M. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 1997, 51:913-921.
51. Zolk O., Solbach T.F., Konig J., Fromm M.F. Functional characterization of the human organic cation transporter 2 variant p. 270Ala>Ser. Drug Metab. Dispos. 2009, 37:1312-1318.
52. Zwart R., Verhaagh S., Buitelaar M., Popp-Snijders C., Barlow D.P. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol. Cell. Biol. 2001, 21:4188-4196.